Overview

Pharmacological Enhancement for Nocturnal Incontinence in Orthotopic Bladder Substitute

Status:
Completed
Trial end date:
2020-03-01
Target enrollment:
Participant gender:
Summary
In this randomised trial, we hypothesised that mebeverine could enhance nocturnal continenece of Orthotopic Bladder Substitute (OBS) patients by decreasing the frequency and reduce maximum amplitude of uninhibited contractions of OBS ileum, and consequently it would increase the OBS capacity
Phase:
N/A
Details
Lead Sponsor:
Mansoura University
Treatments:
Mebeverine